For research use only. Not for therapeutic Use.
Selective antagonist of the glycine site on the NMDA receptor complex. ZD9379 crosses the blood-brain barrier and is neuroprotective. In vivo studies demonstrated reduced infarct size and less spreading depressions after treatment with ZD 9379.
| Catalog Number | R036104 |
| CAS Number | 170142-20-8 |
| Molecular Formula | C19H14ClN3O4 |
| Purity | ≥95% |
| IUPAC Name | 7-chloro-2-(4-methoxy-2-methylphenyl)-3,5-dihydropyridazino[4,5-b]quinoline-1,4,10-trione |
| InChI | InChI=1S/C19H14ClN3O4/c1-9-7-11(27-2)4-6-14(9)23-19(26)15-16(18(25)22-23)21-13-8-10(20)3-5-12(13)17(15)24/h3-8H,1-2H3,(H,21,24)(H,22,25) |
| SMILES | CC1=C(C=CC(=C1)OC)N2C(=O)C3=C(C(=O)N2)NC4=C(C3=O)C=CC(=C4)Cl |
| Reference | T.M. Bare et al. Pyridazino[4,5-b]quinolinediones: novel glycine/N-methyl-D-aspartate antagonists for the treatment of stroke. J. Heterocyclic Chem. 1998, 35, 1171-1186.
T. Tatlisumak et al. A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Acta Neurochir. Suppl. 2000, 76, 331-333.
K. Takano et al. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Stroke. 1997, 28, 1255-1262. |
